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Abstract
Ambulatory blood pressure (BP) monitoring provides valuable information on a person’s BP
phenotype. Abnormal ambulatory BP phenotypes include white-coat hypertension, masked
hypertension, nocturnal nondipping, nocturnal hypertension, and high BP variability. Compared to
people with sustained normotension (normal BP in the clinic and on ambulatory BP monitoring),
the limited research available suggests that the risk of developing sustained hypertension
(abnormal BP in the clinic and on ambulatory BP monitoring) over 5 to 10 years is approximately
two to three times greater for people with white-coat or masked hypertension. More limited data
suggest that nondipping might predate hypertension, and no studies, to our knowledge, have
examined whether nocturnal hypertension or high ambulatory BP variability predict hypertension.
Ambulatory BP monitoring may be useful in identifying people at increased risk of developing
sustained hypertension, but the clinical utility for such use would need to be further examined.
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Hypertension is one of the most important risk factors for cardiovascular disease (CVD),
which remains the leading cause of death in America [1]. In the United States (US), on
average, the risk of developing hypertension over a lifetime is approximately 90% [2]. The
short-term risk of incident hypertension is highest for blacks and lowest for whites up until
75 years of age [new 3]. An estimated 40% of CVD mortality is due to high blood pressure
[1]. Thus, primary prevention of hypertension is an important public health goal [4]. Primary
prevention of hypertension from a clinical standpoint consists of identifying patients who
are “pre-hypertensive” and counseling them to lose weight if warranted, reduce sodium
intake, adopt the DASH (Dietary Approaches to Stop Hypertension) eating plan [5],
exercise, and limit alcohol intake [6]. While these lifestyle changes can help prevent or
delay the onset of hypertension, clinical effectiveness at getting patients with
“prehypertension” to adopt them is extremely limited [7-9].
In addition to the category of prehypertension itself [6], several risk scores for hypertension
have been developed [10]. The underlying basis for developing such scores is that targeting
people most at risk in the shorter term might increase the effectiveness of preventive
interventions such as lifestyle recommendations. Identifying those at higher risk may also
permit use of more aggressive interventions such as specialized weight loss or exercise
programs. People whose short-term risk is increased can also be monitored more closely for
development of hypertension. Not surprisingly, in all of the hypertension risk models, a
person’s blood pressure (BP) level is one of the most important predictors [10].
Through the use of 24-hour ambulatory BP monitoring [11], it has become evident that
people exhibit several BP patterns (Table 1). The pairing of office BP measurement(s) with
average BP derived from ambulatory BP data yields four major phenotypes of BP: sustained
normotension, white-coat hypertension, masked hypertension, and sustained hypertension
(Figure 1). Ambulatory BP monitoring also uniquely provides measures of BP during sleep
which can be used to calculate mean sleep BP. Normally during sleep, BP decreases (“dips”)
such that sleep BP average is lower than awake BP average (Figure 2). The “normal” dip is
considered 10%-20% [12]. Individuals who dip <10% are said to exhibit the nondipper
phenotype (although this category includes “mild dippers” who dip but do so less than 10%).
Nondippers whose sleep BP average is actually greater than their awake BP average are
described as “risers”, and dippers who exceed 20% are sometimes referred to as “extreme
dippers”. Ambulatory BP measurements can also be used to derive other measures of
variability such as standard deviation and average real variability [13]. Thus, “high
ambulatory BP variability” represents another phenotype.
While we are aware of no risk score that incorporates ambulatory BP, people with abnormal
BP phenotypes might be at greater risk of developing sustained hypertension than people
whose BP pattern is considered normal or optimal. Herein, we summarize relevant literature
examining the risk of developing sustained hypertension according to baseline ambulatory
BP phenotype. Given the limited data available, we also included studies that categorized
baseline BP phenotype using home BP monitoring.
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For the purpose of this paper, we preferred studies that examined incident hypertension
based on 24-hour ambulatory BP monitoring. Often, such studies would also include
measurements of BP taken in the office setting. As shown in Figure 1, when office BP and
ambulatory or home BP average are both elevated, the term “sustained” hypertension is
used. Incident hypertension could also be based on office BP readings alone if 24-hour
ambulatory BP or home BP was not available. However, in such instances it is impossible to
know whether the incident hypertension is white-coat or sustained.
PHENOTYPES AND RISK FOR SUSTAINED HYPERTENSION
Sustained Normotension
Sustained normotension is defined as non-elevated office BP (<140/90 mm Hg) and normal
ambulatory BP (i.e. daytime ambulatory BP average < 135/85 mm Hg or 24-hour
ambulatory BP average <130/80 mm Hg) or home BP average < 135/85 mm Hg. Compared
to persons with abnormal BP phenotypes discussed below, a person with sustained
normotension, especially if office BP is optimal (i.e., <120/80 mm Hg) by conventional
standards, has the lowest risk of developing hypertension, at least in the short-term. For
example, one study showed that among people with sustained normotension at baseline,
approximately 18% had sustained hypertension 10 years later [14]. In another study
conducted in Japan that used home BP measurements for out-of-office assessments, 22% of
adults 40 years and older who had sustained (home BP) normotension at baseline had
developed sustained (home BP) hypertension (elevated office BP defined as ≥140/90 mm
Hg, and elevated home BP defined as ≥ 135/85 mm Hg or start of treatment with
antihypertensive medication) 8 years later [15].
White-Coat Hypertension
White-coat hypertension is said to be present when office BP is elevated (≥140/90 mm Hg)
with normal ambulatory BP (i.e. daytime ambulatory BP < 135/85 mm Hg or 24-hour
ambulatory BP <130/80 mm Hg) or home BP (< 135/85 mm Hg).
In the PAMELA study, Mancia and colleagues examined 1412 adults whose ages ranged
from 25 to 74 years at baseline. Participants had office visit BP measurements and 24-hour
ambulatory BP monitoring at baseline and 10 years later [14]. At baseline there were 758
participants categorized as sustained normotensive and 225 categorized as white-coat
hypertensive. Of the participants with white-coat hypertension at baseline, 43% had
sustained hypertension 10-years later compared to 18% among those with sustained
normotension at baseline. After adjusting for age and sex, and excluding any participants on
BP-lowering medications, the odds of developing sustained hypertension were
approximately three times that of those with sustained normotension (aOR 3.25; 95% CI
2.08-5.07). A similar percentage was noted in the Japanese home BP measurement study
mentioned above, in which 47% of those with white-coat hypertension at baseline had
developed sustained (home BP) hypertension 8 years later [15]. After adjustment for
multiple confounders, the odds ratio for development of sustained (home BP) hypertension
was 2.9 (95% CI 1.9-4.3) [15].
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People whose office BP is <140/90 mm Hg but whose 24-hour ambulatory BP or home BP
average is elevated (Table) are classified as having masked hypertension. In the PAMELA
study described above, of the participants with masked hypertension at baseline (n=124),
47% had sustained hypertension 10-years later [14]. After adjusting for age and sex, and
excluding any participants taking BP-lowering medications, the odds of developing
sustained hypertension were approximately 1.7 times that of those with sustained
normotension (aOR 1.65; 95% CI 1.27-2.15). In another study of 1669 white-collar workers,
232 had masked hypertension at baseline [16]. At three years, 26% of those with masked
hypertension had sustained hypertension; and at five years, 35% had sustained hypertension.
Another study with average follow-up of 6 to 7 years found a 42% incidence of sustained
hypertension among adults with masked hypertension compared to a 17% incidence among
those with sustained normotension [17].
Nondipping Pattern
As mentioned earlier, a nondipping pattern is defined as sleep BP average that decreases less
than 10% relative to awake ambulatory BP average. It has been suggested that nondipping in
younger adults might predate hypertension, possibly due to an early autonomic imbalance as
a contributor [18]. In one analysis of 264 adults (mean age 30 years) who had ambulatory
BP monitoring, 118 were nondippers [18]. Baseline office BP was 107/72 mm Hg. Over a
follow-up of 15 years, the incidence of a change to office prehypertension or hypertension
was 36/1000 person-years (64 out of 118) among non-dippers compared to 29/1000 person-
years (64 out of 146) among dippers. When adjusted for race, age, baseline clinic BP, and
other factors, the difference was not significant. However, the study was limited by a small
sample size as well as office BP that was low at baseline. Additionally, participants did not
have follow-up ambulatory BP monitoring, so it is not known whether participants with
incident hypertension had sustained or white-coat hypertension.
Nocturnal Hypertension
Nocturnal hypertension is defined as sleep BP average of ≥120/70 mm Hg during
ambulatory BP monitoring. It can occur with daytime (awake) hypertension or in isolation
[19]. It can also occur in dippers or nondippers but appears superior to nondipping status as
a predictor of cardiovascular disease risk [20]. We are aware of no studies that have
examined the incidence of sustained hypertension according to baseline nocturnal
hypertension status.
High Ambulatory BP Variability
Ambulatory BP variability can be reported as a standard deviation of the BP readings from
the 24-hour period or as average real variability (ARV). ARV is calculated as the average
absolute difference between consecutive readings over the 24 hours and therefore is
sensitive to the order of BP measurements over the monitoring period. “High” variability is
usually defined as the highest percentile (e.g., quartile) in the sample being studied. On
ABPM, ARV is a better predictor of cardiovascular risk than the traditional SD [13,21].
While research shows that higher ARV is associated with cardiovascular disease [22], we
Viera and Shimbo Page 4













are aware of no studies that have examined the incidence of hypertension according to levels
of ARV.
DISCUSSION
While there are a number of studies that demonstrate the increased CVD-related risk
associated with certain abnormal ambulatory BP phenotypes [22-27], few studies have
examined the risk of hypertension according to these phenotypes. Despite relatively limited
data, however, it does appear that people with white-coat or masked hypertension are at two
to three times the risk of developing sustained hypertension over 5 to 10 years compared to
those with sustained normotension. It also appears that people with normal ambulatory BP
averages but a nondipping nocturnal BP pattern may be at increased risk of developing
hypertension. We are aware of no studies that examined the risk of sustained hypertension
associated with nocturnal hypertension or across strata of ambulatory BP variability. Studies
that have used home BP instead of ambulatory BP monitoring have found similar results,
although it is not certain that these methods are interchangeable for identifying out-of-office
BP phenotypes [28].
In current US clinical practice, most people who have ambulatory BP do so for evaluation of
possible white-coat effect. Most evidence demonstrates that people with white-coat
hypertension have CVD risk similar to, or only slightly greater than, people with true
normotension, and therefore do not need to be offered BP-lowering medications [27,29].
Given the increased short-term risk of sustained hypertension, it seems prudent to monitor
such patients more closely for development of hypertension. Additionally, a push for more
aggressive lifestyle modifications may be worthwhile. Masked hypertension poses a
different challenge. If a person is identified as having masked hypertension, BP-lowering
treatment might actually be warranted based on the fact that the CVD risk among such
patients approaches that of those with sustained hypertension. However, there are currently
no trials that have demonstrated a reduction in CVD events by treating masked
hypertension. It seems clear at the very least such patients should be monitored closely for
development of sustained hypertension.
In addition to the small number of studies that have examined the incidence of hypertension
according to ambulatory BP phenotypes, the existing research has a number of limitations.
Studies have been limited in terms of the population enrolled. For example, studies may
have only included only Caucasions (PAMELA) [14]. Given that Blacks have a higher
prevalence and severity of hypertension, the risk based on ambulatory BP phenotype may
differ. We know, for instance, that Blacks have a higher prevalence of nondipping [18].
A systematic review of hypertension risk models is notable for the fact that no models
include baseline ambulatory BP measures [10]. Risk prediction might be refined by
including such measures. An additional important point to note about research on
hypertension risk is that any study that categorizes incident hypertension solely by office BP
is limited as it would not necessarily reflect sustained hypertension.
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People with white-coat and masked hypertension are two to three times more likely to
develop sustained hypertension over 5 to 10 years. It also appears that nondipping might be
a harbinger of developing hypertension. We know of no studies examining whether
nocturnal hypertension or high ambulatory BP variability among people with otherwise
normal ambulatory BP average predict hypertension. In addition to its value in diagnosis and
management of hypertension, ambulatory BP monitoring may be useful in identifying some
groups at increased short-term risk of developing hypertension. Further research is needed to
learn whether such use is clinically effective at preventing or delaying hypertension.
Acknowledgments
This article was partially supported by grants R01-HL098604 (Dr. Viera) and P01-HL047540 (Dr. Shimbo) from
the National Heart, Lung, and Blood Institute at the National Institutes of Health (NIH).
References
Papers of particular interest, published recently, have been highlighted as:
* Of importance
**Of major importance
1. Go AS, Mozaffarian D, Roger VL, et al. American Heart Association Statistics Committee and
Stroke Statistics Subcommittee.Executive summary: heart disease and stroke statistics--2014
update: a report from the American Heart Association. Circulation. Jan 21; 2014 129(3):399–410.
⍰ . doi: 10.1161/01.cir.0000442015.53336.12. Presents the most recent statistics on cardiovascular
disease including the contributions of hypertension. [PubMed: 24446411]
2. Carson AP, Howard G, Burke GL, Shea S, Levitan EB, Muntner P. Ethnic differences in
hypertension incidence among middle-aged and older adults: the Multi-ethnic Study of
Atherosclerosis. Hypertension. 2011; 57:1101–07. [PubMed: 21502561]
3. Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in middle-
aged women and men: The Framingham Heart Study. JAMA. 2002; 287(8):1003–10. [PubMed:
11866648]
4. Whelton PK, He J, Appel LJ, et al. National High Blood Pressure Education Program Coordinating
Committee. Primary prevention of hypertension: clinical and public health advisory from The
National High Blood Pressure Education Program. JAMA. Oct 16; 2002 288(15):1882–8. [PubMed:
12377087]
5. Sacks FM, Svetkey LP, Vollmer WM, et al. DASH-Sodium Collaborative Research Group.Effects
on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension
(DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med. Jan 4; 2001 344(1):3–
10. [PubMed: 11136953]
6. Chobanian AV, Bakris GL, Black HR, et al. National Heart, Lung, and Blood Institute Joint
National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure;
National High Blood Pressure Education Program Coordinating Committee.. The Seventh Report of
the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood
Pressure: the JNC 7 report. JAMA. 2003; 289(19):2560–2572. [PubMed: 12748199]
7. Viera AJ, Lingley K, Esserman D. Effects of labeling patients as prehypertensive. J Am Board Fam
Med. 2010; 23(5):571–83. [PubMed: 20823351]
8. Viera AJ, Bangura F, Mitchell CM, Cerna A, Sloane P. Do clinicians tell patients they have
prehypertension? J Am Board Fam Med. 2011; 24(1):117–8. [PubMed: 21209353]
Viera and Shimbo Page 6













9. Spruill TM, Feltheimer SD, Harlapur M, et al. Are there consequences of labeling patients with
prehypertension? An experimental study of effects on blood pressure and quality of life. J
Psychosom Res. May; 2013 74(5):433–8. [PubMed: 23597332]
10. Echouffo-Tcheugui JB, Batty GD, Kivimäki M, Kengne AP. Risk models to predict hypertension:
a systematic review. PLoS One. Jul 5.2013 8(7):e67370. ⍰ . This article provides a review of the
available hypertension risk models and scores. [PubMed: 23861760]
11. Pickering TG, Shimbo D, Haas D. Ambulatory blood pressure monitoring. N Engl J Med. 2006;
354:2368–74. [PubMed: 16738273]
12. O'Brien E, Parati G, Stergiou G, et al. European Society of Hypertension Working Group on Blood
Pressure Monitoring. European society of hypertension position paper on ambulatory blood
pressure monitoring. J Hypertens. Sep; 2013 31(9):1731–68. ⍰ . doi: 10.1097/HJH.
0b013e328363e964. Presents comprehensive, up-to-date information on all aspects of ambulatory
blood pressure monitoring. [PubMed: 24029863]
13. Pierdomenico SD, Di Nicola M, Esposito AL, et al. Prognostic value of different indices of blood
pressure variability in hypertensive patients. Am J Hypertens. 2009; 22(8):842–847. [PubMed:
19498342]
14. Mancia G, Bombelli M, Facchetti R, et al. Long-term risk of sustained hypertension in white-coat
or masked hypertension. Hypertension. Aug; 2009 54(2):226–32. ⍰ . This article provides some of
the leading evidence of the risk of sustained hypertension for people with white-coat and masked
hypertension. [PubMed: 19564548]
15. Ugajin T, Hozawa A, Okhubo T, et al. White-coat hypertension as a risk factor for the
development of home hypertension. Arch Intern Med. 2005; 165:1541–46. [PubMed: 16009871]
16. Trudel X, Milot A, Brisson C. Persistence and progression of masked hypertension: a 5-year
prospective study. Int J Hypertens. 2013; 2013:836387. ⍰ . doi: 10.1155/2013/836387. This article
examines what happens to blood pressure in people identified with masked hypertension 5 years
later. [PubMed: 24455208]
17. Pierdomenico SD, Pannarale G, Rabbia F, et al. Prognostic relevance of masked hypertension in
subjects with prehypertension. Am J Hypertens. 2008; 21(8):879–83. [PubMed: 18464744]
18. Viera AJ, Zhu S, Hinderliter AL, Shimbo D, Person SD, Jacobs DR Jr. Diurnal blood pressure
pattern and development of prehypertension or hypertension in young adults: the CARDIA study.
J Am Soc Hypertens. 2011; 5(1):48–55. [PubMed: 21269909]
19. Li Y, Wang J. Isolated nocturnal hypertension: a disease masked in the dark. Hypertension. 2013;
61:278–83. [PubMed: 23248146]
20. Tsioufis C, Andrikou I, Thomopoulos C, Syrseloudis D, Stergiou G, Stefanadis C. Increased
nighttime blood pressure or nondipping profile for prediction of cardiovascular outcomes. J Hum
Hypertens. 2011; 25:281–293. [PubMed: 21124340]
21. Mena L, Pintos S, Queipo NV, JAizpúrua JA, Maestre G, Sulbarán T. A reliable index for the
prognostic significance of blood pressure variability. J Hypertens. 2005; 23(3):505–511. T.
[PubMed: 15716690]
22. Stolarz-Skrzypek K, Thijs L, Li Y, et al. Short-term blood pressure variability in relation to
outcome in the International Database of Ambulatory blood pressure in relation to Cardiovascular
Outcome (IDACO). Acta Cardiol. Dec; 2011 66(6):701–706. [PubMed: 22299379]
23. Yamaguchi Y, Wada M, Sato H, et al. Impact of Ambulatory Blood Pressure Variability on
Cerebral Small Vessel Disease Progression and Cognitive Decline in Community-Based Elderly
Japanese. Am J Hypertens. Mar 20.2014 ⍰ . [Epub ahead of print] A recent study of the
association of ambulatory blood pressure variability with cognitive outcomes.
24. Verberk WJ, Kessesl AG, de Leeuw PW. Prevalence, causes, and consequences of masked
hypertension: a meta-analysis. Am J Hypertens. 2008; 21:969–975. [PubMed: 18583985]
25. Fagard RH, Cornelissen VA. Incidence of cardiovascular events in white-coat, masked and
sustained hypertension versus true normotension: a meta-analysis. J Hypertens. 2007; 25:2193–
2198. [PubMed: 17921809]
26. Brguljan-Hitij J, Thijs L, Li Y, Hansen TW, et al. Risk Stratification by Ambulatory Blood
Pressure Monitoring Across JNC Classes of Conventional Blood Pressure. Am J Hypertens. Feb
26.2014 ⍰ . on behalf of the International Database on Ambulatory blood pressure in relation to
Viera and Shimbo Page 7













Cardiovascular Outcome Investigators. [Epub ahead of print] Uses the large IDACO database to
examine outcomes across different BP phenotypes.
27. Ohkubo T, Kikuya M, Metoki H, et al. Prognosis of "masked" hypertension and "white-coat"
hypertension detected by 24-h ambulatory blood pressure monitoring 10-year follow-up from the
Ohasama study. J Am Coll Cardiol. Aug 2; 2005 46(3):508–15. [PubMed: 16053966]
28. Viera AJ, Lin FC, Tuttle LA, Olsson E, Stankevitz K, Girdler SS, Klein JL, Hinderliter AL.
Reproducibility of masked hypertension among adults 30 years or older. Blood Press Monit. May
16.2014 [Epub ahead of print].
29. Krause T, Lovibond K, Caulfield M, McCormack T, Williams B. Guideline Development Group.
Management of hypertension: summary of NICE guidance. BMJ. 2011; 343:d4891. doi:10.1136/
bmj.d4891. [PubMed: 21868454]
Viera and Shimbo Page 8














Ambulatory Blood Pressure Phenotypes Based on Pairing Office and Ambulatory
Measurements
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Figure 2. A 24-Hour Ambulatory Blood Pressure Monitoring Graph
The 24-hour period of monitoring is divided primarily into awake (often called “daytime”)
and sleep (often called “nocturnal”) periods (shaded section in above graph). Sometimes, to
improve tolerability of wearing the monitor, readings are taken at less frequent intervals
during the sleep period. A diary is often used as the basis by which to define sleep time,
although some studies use a specified period (e.g., midnight to 6am) to denote sleep time.
Based on the time periods, a person’s awake (or daytime) BP average can be calculated, as
can their sleep (or nocturnal) average. Shown above is the graph of a person whose awake
average (based on 31 measurements) was 128/81 (±14/11) mm Hg and sleep average (based
on 7 measurements) was 108/64 (±13/11) mm Hg. The nocturnal systolic dip is calculated as
(128-108)/128, which is approximately 16%. The lowest line on the graph shows heart rate.
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Table 1
Major Ambulatory Blood Pressure Phenotypes
Phenotype Usual Definition
Sustained normotension Office BP is not elevated AND 24-hour ambulatory BP average is
<130/80 mm Hg
White-coat hypertension Office BP is elevated BUT 24-hour ambulatory BP average is <130/80
mm Hg
Masked hypertension Office BP is not elevated BUT 24-hour ambulatory BP average is
≥130/80 mm Hg (or awake average is ≥135/85 mm Hg)
Sustained hypertension Office BP is elevated AND 24-hour ambulatory BP average is
≥130/80 mm Hg (or awake average is ≥135/85 mm Hg)
Nocturnal hypertension Sleep BP average ≥120/70 mm Hg




Average absolute difference between consecutive readings over the
24 hours; “high” variability usually defined as the highest percentile
(e.g., quartile) in the sample
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